news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Meijing AI News,SPDB International Securities released a research report on August 20, giving Rongchang Biopharma (688331.SH) a hold rating. The main reasons for the rating include: 1) 2Q24 revenue slightly exceeded our expectations, but the net loss was significantly higher than our expectations; 2) Taitasip achieved sales of 380 million yuan in the first half of the year, slightly better than our previous expectations; 3) Both RC18 international phase III clinical trials began to enroll the first patient in the second half of the year. We conservatively predict that R&D expenses in the second half of the year will increase compared with the first half of the year. Risk warning: overseas authorization delays or failures, cash flow consumption greater than expected, sales not as expected, R&D delays or clinical trial data not as expected.

AI comment: Rongchang Biopharma has received research attention from 2 brokerage firms in the past month, and 1 of them was bought.

Every headline (nbdtoutiao)——

(Reporter Cai Ding)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. You will be responsible for your own risks if you act accordingly.

Daily Economic News